Being supported by the biology of these two sublineages and the clinical evidence of the correlation between donor iNKT persistence and lower incidences of GvHD, preclinical studies have broadened the road for potential allogeneic therapies that utilize CD4+ or CD4-CD94+ iNKT cells as the source. The gene discussed is CD4; the disease is graft versus host disease.